Portal de Periódicos da CAPES

Abstract 2829: A novel candidate for immunotherapy mediating the balance between the immune system and cancer

2020; American Association for Cancer Research; Volume: 80; Issue: 16_Supplement Linguagem: Inglês

10.1158/1538-7445.am2020-2829

1538-7445

Elisa Pesce, Chiara Cordiglieri, Cristina Manara, Stefania Oliveto, Susanna Campagnoli, Tiziano Donnarumma, Manuele Martinelli, Mariacristina Crosti, Elisa De Camilli, Stefano Biffo, Sergio Abrignani, Mauro Bombaci, Renata Grifantini, Andrea Gobbini,

Glycosylation and Glycoproteins Research

Abstract Cytotoxic CD8+ T cells are considered as one of the main populations of effector immune cells in antitumor immunity. The absence of CD8+ T cells in the central tumor area has become a major obstacle for solid tumor immunotherapy. Thus, novel therapeutic strategies that could promote CD8+ T cells to accumulate in the central tumor area are urgently needed. To this aim, we want to propose a novel candidate INGM01 a highly glycosylated mucin-like protein localized on the cell surface and so far poorly characterized. High INGM01 expression is reported to be associated to a higher survival rate in some cancers (PreCOG database). We found that INGM01 is physiologically expressed on the surface of different cancer human cell lines and its over-expression by cDNA transfection significantly increased motility and migration phenotypes, such as improved scratch recovery in the wound healing assay, altered cytoskeleton organization with loss of actin branches, reduced E-cadherin expression and activated Fak pathway through phosphorylation of its Y925. We also found that INGM01 is specifically over-expressed in tumor-infiltrating CD8+ and CD4+ lymphocytes, as judged by IHC and IF analysis of cryopreserved tissues and by FACS analysis of T cells isolated from different cancers (e.g. colon, kidney), while it is marginally expressed in T-cells resident in adjacent normal tissues. Microscopy analysis showed that INGM01 localizes in anchoring sites of CD8+ T-cells attacking the cancer cells forming a cluster of lymphocytes on their surface. INGM01 expression in T lymphocyte is significantly induced by CD3/CD28 receptor activation and by the microenvironmental milieu conditioned by cancer cells, through the production of soluble factors. Indeed, INGM01 is localized in the uropod of both CD3/28 activated and ex vivo isolated tumor infiltrating CD4+ and CD8+ T cells confirming a role of INGM01 in motility of the T-cells. We found INGM01 co-expressed with other uropod-associated proteins, such as ICAM-I, LFA-1 and CXCR-3, involved in the acquisition of the polarity needed for T-cell chemotaxis and for migration. By Boyden chamber, with and without a HUVEC cell monolayer, we found that INGM01 positive CD8+ and Jurkat cells migrate towards wells containing conditioned medium of cancer cells and this process is significantly impaired by INGM01 silencing indicating its role in chemotaxis and trans-endothelial migration. Furthermore, INGM01 contributes to the cytotoxic function of CD8+ T-cells, since its silencing causes a reduction of expression of Th1 effector cytokines, such as IFN-γ, TNFα. Our hypothesis is that, after a deeper analysis of the interaction/s and ligand/s involving INGM01, it might be possible to generate affinity agents or bi-spefic antibodies able to enhance the intratumoral infiltration of cytotoxic CD8+ T-cells expressing INGM01 and their migration towards cancer cells, to promote their killing. Citation Format: Elisa Pesce, Chiara Cordiglieri, Cristina Manara, Stefania Oliveto, Susanna Campagnoli, Tiziano Donnarumma, Manuele Martinelli, Mariacristina Crosti, Elisa De Camilli, Stefano Biffo, Sergio Abrignani, Mauro Bombaci, Renata Maria Grifantini, Andrea Gobbini. A novel candidate for immunotherapy mediating the balance between the immune system and cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2829.